Send to

Choose Destination
Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

Author information

Department of Medicine, University of Chicago, Chicago, Illinois.
Department of Medicine, University of Chicago, Chicago, Illinois.
Departments of Biology and Computer Science, Loyola University Chicago, Chicago, Illinois.
Division of Genetic Medicine, Vanderbilt University, Nashville, Tennessee.
Department of Medical Oncology, Indiana University, Indianapolis, Indiana.
Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Oncology, Oslo University Hospital, Radiumhospital, Oslo, Norway.
Department of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan.
RIKEN Center for Integrative Medical Science, Yokohama, Japan.


Purpose: Our purpose was to characterize the clinical influences, genetic risk factors, and gene mechanisms contributing to persistent cisplatin-induced peripheral neuropathy (CisIPN) in testicular cancer survivors (TCSs).Experimental Design: TCS given cisplatin-based therapy completed the validated EORTC QLQ-CIPN20 questionnaire. An ordinal CisIPN phenotype was derived, and associations with age, smoking, excess drinking, hypertension, body mass index, diabetes, hypercholesterolemia, cumulative cisplatin dose, and self-reported health were examined for 680 TCS. Genotyping was performed on the Illumina HumanOmniExpressExome chip. Following quality control and imputation, 5.1 million SNPs in 680 genetically European TCS formed the input set. GWAS and PrediXcan were used to identify genetic variation and genetically determined gene expression traits, respectively, contributing to CisIPN. We evaluated two independent datasets for replication: Vanderbilt's electronic health database (BioVU) and the CALGB 90401 trial.Results: Eight sensory items formed a subscale with good internal consistency (Cronbach α = 0.88). Variables significantly associated with CisIPN included age at diagnosis (OR per year, 1.06; P = 2 × 10-9), smoking (OR, 1.54; P = 0.004), excess drinking (OR, 1.83; P = 0.007), and hypertension (OR, 1.61; P = 0.03). CisIPN was correlated with lower self-reported health (OR, 0.56; P = 2.6 × 10-9) and weight gain adjusted for years since treatment (OR per Δkg/m2, 1.05; P = 0.004). PrediXcan identified lower expressions of MIDN and RPRD1B, and higher THEM5 expression as associated with CisIPN (P value for each < 5 × 10-6) with replication of RPRD1B meeting significance criteria (Fisher combined P = 0.0089).Conclusions: CisIPN is associated with age, modifiable risk factors, and genetically determined expression level of RPRD1B Further study of implicated genes could elucidate the pathophysiologic underpinnings of CisIPN. Clin Cancer Res; 23(19); 5757-68. ©2017 AACR.

[Indexed for MEDLINE]
Free PMC Article

MeSH terms, Substances, Grant support

MeSH terms


Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center